Small molecule disease-modifying agent

This page covers all Small molecule disease-modifying agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Phase 3 pipeline (1)

• ALZT-OP1b · AZTherapies, Inc. · Neurology
  ALZT-OP1b is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease.

Patent intelligence

• small molecule disease modifying agent patent landscape — aggregated cliff calendar, attackable patents, originator estates